Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolEPA:SAN
CUSIPN/A
Phone+33-1-53774000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-0.27%
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares1,260,000,000
Sanofi (EPA:SAN) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the EPA under the ticker symbol "SAN."
What price target have analysts set for SAN?
16 brokers have issued 12-month target prices for Sanofi's stock. Their forecasts range from €60.00 to €94.00. On average, they expect Sanofi's share price to reach €77.63 in the next year. View Analyst Ratings for Sanofi.
Who are some of Sanofi's key competitors?
Some companies that are related to Sanofi include Bayer (BAYN), GlaxoSmithKline (GSK), AstraZeneca (AZN), BEXIMCO PHARMAC/S GDR REGS (BXP), OTSUKA HOLDINGS/ADR (OTSKY), Hutchison China MediTech (HCM), Dechra Pharmaceuticals (DPH), Mayne Pharma Group (MYX), Vectura Group (VEC), Eco Animal Health Group (EAH), Trilogy International Partners (TRL), Allergy Therapeutics (AGY), Sinclair Pharma (SPH), Pharmaxis (PXS) and NanoViricides (NNVC).
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 62)
- Mr. Jérôme Contamine, CFO & Exec. VP (Age 61)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
Has Sanofi been receiving favorable news coverage?
Press coverage about SAN stock has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sanofi earned a news impact score of 0.05 on Accern's scale. They also gave media stories about the company an impact score of 44.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
What is Sanofi's stock price today?
One share of SAN stock can currently be purchased for approximately €66.17.
How big of a company is Sanofi?
Sanofi has a market capitalization of $82.98 billion.
How can I contact Sanofi?
Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.
MarketBeat Community Rating for Sanofi (SAN)
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
